VISION
VISION is an active learning platform that uses tumor, immune system and health data to predict the best treatment options.
How does VISION work?
- Leveraging advanced analytics
utilizing the Agenus data repository to explore an immense range of drug-biology interactions not possible via traditional processes. This includes in silico modeling and AI.
- Making predictions informed by laboratory experiments
that test how our drugs perform under conditions that mimic a patient’s tumor and immune system.
- Getting the right drug to the right patient at the right time
designed to unlock the true potential of our broad immunotherapy portfolio.
The Agenus data repository comprises:
0
+
single cell profiles defining the immune stimulation response to anti-CTLA-4 therapy
Outcome: Biomarkers to accelerate development of botensilimab as monotherapy and in effective combinations
0
+
data points defining the life cycle of a T cell from activation to exhaustion, including the effects of anti-PD-1 therapy
Outcome: Accelerated clinical path for PD-1 combinations
0
+
unique peptides expressed on patient tumors across multiple cancer types
Outcome: Prioritized novel cancer therapeutic targets
0
+
proprietary immunotherapies evaluated across 10+ preclinical in vivo tumor models to gather pharmacodynamic data
Outcome: Bridges research hypotheses from the bench to the clinic
VISION Empowers
